Movement Alert｜Recursion Pharmaceuticals, Inc. Intraday Rise 8.02% in Regular Trading, Webinar to Highlight Updated REC-4881 Data

Market Focus10-28 22:18

On October 28, Recursion Pharmaceuticals, Inc. rose 8.02% in Regular Trading, trading at $4.3701/share, with turnover of $24.7915 million.

The move followed the company’s announcement that it will host a November 3 webinar focused on updated REC-4881 data from CGA-IGC, alongside earnings updates, as well as KOL and patient panel discussions.

Supporting context shows the company recently disclosed that Sanofi selected the first drug candidate from their collaboration, triggering a $10 million milestone payment. Recursion said total upfront and milestone payments under that partnership have reached $144 million, with eligibility for more than $300 million in additional milestones and double-digit royalties on net sales. The Sanofi-optioned inflammatory disease candidate is planned to enter phase 1 in 2027.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment